Hi Lars!

After 18 years on the board of SwedenBIO, Lars Adlersson is now passing the baton to Lotta Ljungqvist. We ask Lars about what's next and what he has enjoyed most during his years as President.

What are you going to do now?

– I will have some more time to continue growing Adlersson Heath where we help life science companies communicate with the capital market, but also provide strategic advice to decision makers in completely different sectors of society. I also sit on the board of Irlab Therapeutics, a company developing new drugs for Parkinson’s disease, which is listed on the Nasdaq main board. So the days will continue to pass quickly!

What has been the most fun and what will you miss?

– It has been fun to contribute to and follow SwedenBIO’s development. Originally a small discussion club for a few biotech CEOs, it has evolved into a broad and powerful industry organization with almost 300 members. I’m a party to the case, but I really believe that SwedenBIO’s meeting places, knowledge building and political advocacy have contributed to the strong development of the Swedish life science industry. I have enjoyed working with an office that is truly passionate about the industry. But I don’t have to miss anyone, as I have been kindly asked to take on a role as a senior advisor to the association on issues related to our members’ business development and funding opportunities. I am also taking a seat on the nomination committee.


Much has happened in the industry since you joined the board in 2003. How would you sum up the industry’s journey over the last 18 years?

– The most obvious is the huge number of new life science companies. Sometimes I feel that there have even been a few too many; a certain critical mass is required in each individual company, and it is important to maintain high quality everywhere so as not to risk damaging investor confidence in the entire industry. The rising interest in life science among Swedish small investors has been very important for the companies’ financing, but even here I can get a bit worried, over time the companies have to deliver what they promised for the sector to remain attractive. But all in all, I never thought we could develop the industry in this way and the future remains bright.

If we instead look ahead 18 years, i.e. to 2039, what do you think we will see in terms of achievements by the Swedish life science industry?

– I can’t see that far ahead. But long before 2039, I hope we will see the first disease-modified drugs for Alzheimer’s and Parkinson’s diseases, based on Swedish research. Secondly, I believe that everything we have learned about the immune system during the COVID-19 pandemic will open the doors to completely new treatments for inflammatory diseases, but also for sepsis.

In a parallel universe, where you had chosen to become a troubadour instead of entering the life science industry, what would have given you the satisfaction of being able to say that all your goals have been met?

– It would be that against all odds I managed to learn how to sing clean and became so successful that I got a gig at SwedenBIO’s annual executive dinner…

Here is SwedenBIO’s new board.